- Report
- March 2024
- 200 Pages
Global
From €3696EUR$4,150USD£3,223GBP
- Report
- March 2024
- 200 Pages
Global
From €3696EUR$4,150USD£3,223GBP
- Report
- January 2024
- 200 Pages
Global
From €3696EUR$4,150USD£3,223GBP
- Report
- August 2023
- 145 Pages
Global
From €2805EUR$3,150USD£2,446GBP
- Report
- July 2023
- 145 Pages
Global
From €2805EUR$3,150USD£2,446GBP
- Clinical Trials
- April 2025
- 180 Pages
Global
From €2226EUR$2,500USD£1,941GBP
- Report
- April 2025
- 200 Pages
Global
From €7080EUR$7,950USD£6,173GBP
- Clinical Trials
- April 2025
- 80 Pages
Global
From €1781EUR$2,000USD£1,553GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1336EUR$1,500USD£1,165GBP
- Report
- December 2024
- 30 Pages
Global
From €2894EUR$3,250USD£2,524GBP
- Report
- January 2024
- 120 Pages
Global
From €7080EUR$7,950USD£6,173GBP
- Report
- April 2025
- 184 Pages
Global
From €4007EUR$4,500USD£3,494GBP
- Clinical Trials
- April 2025
- 100 Pages
Global
From €1781EUR$2,000USD£1,553GBP
- Report
- January 2024
- 189 Pages
Global
From €6679EUR$7,500USD£5,824GBP
- Report
- September 2022
- 30 Pages
Global
From €2449EUR$2,750USD£2,135GBP
- Report
- May 2025
- 70 Pages
Japan
From €4230EUR$4,750USD£3,689GBP
- Report
- June 2025
- 250 Pages
Canada
From €2484EUR$2,789USD£2,166GBP
- Report
- May 2025
- 300 Pages
Global
From €4407EUR$4,949USD£3,843GBP
- Report
- August 2024
- 150 Pages
Global
From €2484EUR$2,789USD£2,166GBP
- Report
- March 2026
- 136 Pages
France
From €3561EUR$3,999USD£3,105GBP

The Glucagon Like Peptide 1 Agonist (GLP-1) market is a subset of the larger diabetes drugs market. GLP-1 agonists are a class of drugs used to treat type 2 diabetes, and are designed to mimic the effects of the hormone glucagon-like peptide-1 (GLP-1). GLP-1 agonists work by stimulating the release of insulin, reducing the amount of glucose in the blood, and slowing the rate of gastric emptying. GLP-1 agonists are typically administered via injection, and are used in combination with other diabetes medications.
The GLP-1 agonist market is highly competitive, with a number of major pharmaceutical companies offering products. These include Novo Nordisk, Eli Lilly, Sanofi, AstraZeneca, and Boehringer Ingelheim. Show Less Read more